After a lackluster first half of 2025, healthcare stocks staged a comeback, posting the best performance among the 11 S&P 500 ...

Eli Lilly is aware of this fact, which helps explain why it acquired Adverum Biotechnologies in late 2025 and just agreed to ...

Eli Lilly highlighted 2025 as the rollout year for obesity drugs, with Mounjaro at the forefront of its weight-loss portfolio ...

Nimbus will use its AI to help identify drug candidates, while Lilly will contribute its metabolic-disease expertise to ...

SHANGHAI, Dec 8 (Reuters) – Eli Lilly and Co.’s popular drug Mounjaro will be added to China’s state-run health insurance scheme from Jan. 1 for patients with type 2 diabetes, the National Healthcare ...

Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's ...

Eli Lilly is getting its hands on a promising pipeline candidate thanks to an acquisition. The stock may not gain much more ...

Eli Lilly won approval for its tirzepatide under the names Mounjaro for type 2 diabetes and Zepbound for weight loss -- in ...

Eli Lilly briefly reached $1 trillion in market cap last year before retreating. The company has seen revenue soar in recent ...

The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with ...